The recent development of highly specific MMP-9 inhibitors, such as those based on modified peptide sequences that bind directly to the MMP-9 active site, has shown promise in preclinical models by minimizing the invasive capacity and supporting immune cell activity within the tumor microenvironment [63]. Here, MMP9 is linked to neoplasm.